BridgeBio Oncology Therapeutics, Inc.
Ownership
Ownership Structure
Who owns BridgeBio Oncology Therapeutics, Inc. (BBOT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 44.7% of the shares are freely tradable; institutional investors hold 70.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Cormorant Asset Management, LLC | 22.30 | 17,878,594 | +0.0 | 03/31/2026 |
| Deerfield Management Co | 6.09 | 4,885,446 | +0.0 | 03/31/2026 |
| Omega Fund Management LLC | 4.10 | 3,289,661 | +0.0 | 03/31/2026 |
| Alphabet Inc | 3.52 | 2,823,126 | +0.0 | 06/30/2026 |
| EcoR1 Capital, LLC | 3.52 | 2,823,126 | +0.0 | 06/30/2026 |
| Wellington Management Company LLP | 3.48 | 2,789,302 | -1.0 | 06/30/2026 |
| Enavate Sciences GP, LLC | 3.28 | 2,626,946 | +0.0 | 06/30/2026 |
| Citadel Advisors Llc | 3.27 | 2,617,827 | +3.5 | 06/30/2026 |
| Novo A/S | 2.73 | 2,185,923 | +11.5 | 03/31/2026 |
| BlackRock Inc | 2.60 | 2,088,297 | +0.2 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Cobo Marc | Principal Accounting Officer | 14,141 | 56,564 $ | Sep 10, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Cobo Marc | Principal Accounting Officer | Other | 203 | 5.52 | 1,121 |
| Sep 10, 2026 | Cobo Marc | Principal Accounting Officer | Other | 9,038 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.